Key Points

  • Record Revenues: Caterpillar’s centennial year marked a significant milestone with the highest full-year sales and revenues in company history at $67.6 billion, including a single-quarter record of $19.1 billion in Q4.
  • Robust Cash Flow: The enterprise generated strong full-year operating cash flow of $11.7 billion in 2025 and ended the year with an enterprise cash balance of $10.0 billion.
  • Shareholder Value Deployment: During 2025, Caterpillar deployed $7.9 billion of cash for share repurchases and dividends to return value to its shareholders.
hero

Sales Growth Amidst Cost Pressures

Caterpillar announced fourth-quarter 2025 sales and revenues of $19.1 billion, representing an 18% increase compared to $16.2 billion in the fourth quarter of 2024. This growth was primarily driven by higher sales volume across its primary segments. However, fourth-quarter profit per share (GAAP) was $5.12, down from $5.78 in the previous year, largely due to unfavorable manufacturing costs—primarily impacted by higher tariffs—and higher restructuring costs related to the Rail division.

Segment Performance Analysis

Growth in the fourth quarter was visible across all three primary segments:

Power & Energy: This segment saw the strongest growth, with total sales increasing by 23% to $9.4 billion. The surge was led by Oil and Gas (turbines and services) and Power Generation, particularly for data center applications.

Construction Industries: Sales rose by 15% to $6.9 billion, primarily due to higher sales volume of equipment to end users, with a particularly strong performance in North America (up 23%).

Resource Industries: This segment reported a 13% increase in sales to $3.35 billion, mainly driven by changes in dealer inventories.

Financial Stability and Future Outlook

While the operating profit margin for the fourth quarter decreased to 13.9% (compared to 18.0% in Q4 2024), adjusted profit per share for the quarter actually rose slightly to $5.16. CEO Joe Creed stated that the company enters the new year with strong momentum and a record backlog, demonstrating the strength of Caterpillar’s end markets.

Summary

The year 2025 stands as a landmark year for Caterpillar, characterized by record-breaking sales and revenues. Despite headwinds from manufacturing costs and tariffs, the company’s ability to generate massive cash flow while returning billions to shareholders highlights its operational resilience and strong market positioning heading into 2026.


Comparison, examination, and analysis between investment houses

Leave your details, and an expert from our team will get back to you as soon as possible

    * This article, in whole or in part, does not contain any promise of investment returns, nor does it constitute professional advice to make investments in any particular field.

    To read more about the full disclaimer, click here
    SKN | Palantir Q1 Earnings in Focus as AI Momentum and Government Demand Drive Growth
    • Lior mor
    • 5 Min Read
    • ago 10 hours

    SKN | Palantir Q1 Earnings in Focus as AI Momentum and Government Demand Drive Growth SKN | Palantir Q1 Earnings in Focus as AI Momentum and Government Demand Drive Growth

    Strong Revenue Growth Expected Palantir Technologies is set to report its first-quarter earnings, with Wall Street expecting revenue of approximately

    • ago 10 hours
    • 5 Min Read

    Strong Revenue Growth Expected Palantir Technologies is set to report its first-quarter earnings, with Wall Street expecting revenue of approximately

    SKN | UCB to Acquire Candid Therapeutics in $2.2 Billion Deal to Expand Autoimmune Pipeline
    • omer bar
    • 4 Min Read
    • ago 12 hours

    SKN | UCB to Acquire Candid Therapeutics in $2.2 Billion Deal to Expand Autoimmune Pipeline SKN | UCB to Acquire Candid Therapeutics in $2.2 Billion Deal to Expand Autoimmune Pipeline

    Strategic Expansion into Autoimmune Therapies UCB has agreed to acquire California-based Candid Therapeutics in a transaction valued at up to

    • ago 12 hours
    • 4 Min Read

    Strategic Expansion into Autoimmune Therapies UCB has agreed to acquire California-based Candid Therapeutics in a transaction valued at up to

    SKN | Berkshire Hathaway Cash Pile Surges in Greg Abel’s First Quarter as CEO—What It Signals for Markets
    • Ronny Mor
    • 6 Min Read
    • ago 1 day

    SKN | Berkshire Hathaway Cash Pile Surges in Greg Abel’s First Quarter as CEO—What It Signals for Markets SKN | Berkshire Hathaway Cash Pile Surges in Greg Abel’s First Quarter as CEO—What It Signals for Markets

      Berkshire Hathaway reported a sharp rise in its cash reserves during the first quarter under new CEO Greg Abel,

    • ago 1 day
    • 6 Min Read

      Berkshire Hathaway reported a sharp rise in its cash reserves during the first quarter under new CEO Greg Abel,

    SKN | Moderna Beats Revenue Expectations as Global Vaccine Demand Supports International Sales
    • omer bar
    • 6 Min Read
    • ago 2 days

    SKN | Moderna Beats Revenue Expectations as Global Vaccine Demand Supports International Sales SKN | Moderna Beats Revenue Expectations as Global Vaccine Demand Supports International Sales

      Moderna exceeded revenue expectations in its latest quarterly results, supported by continued demand for its COVID-19 vaccine in international

    • ago 2 days
    • 6 Min Read

      Moderna exceeded revenue expectations in its latest quarterly results, supported by continued demand for its COVID-19 vaccine in international